Working… Menu
Trial record 2 of 2 for:    prochondrix

Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03873545
Recruitment Status : Recruiting
First Posted : March 13, 2019
Last Update Posted : April 21, 2021
Information provided by (Responsible Party):

Brief Summary:
The purpose of this clinical study is to evaluate the use of ProChondrix Cryopreserved Osteochondral Allograft to obtain evidence of effectiveness, defined as an improvement in physical function and pain, when used on a symptomatic cartilage defect on the femoral condyle or patella in a mechanically stable knee.

Condition or disease Intervention/treatment
Cartilage Injury Cartilage Damage Procedure: Cryopreserved Osteochondral Allograft

Detailed Description:
This clinical study will use a multi-center, prospective design, to evaluate ProChondrix CR in approximately 80 patients who are scheduled to undergo treatment of a cartilage defect on the femoral condyle or patella.Patient follow-up will include a period of 60 months after surgery. During this follow-up period, each patient will be evaluated seven (7) times at: 3, 6, 12, 24, 36, 48 and 60 months after surgical intervention.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee
Actual Study Start Date : March 18, 2019
Estimated Primary Completion Date : April 1, 2026
Estimated Study Completion Date : December 30, 2026

Intervention Details:
  • Procedure: Cryopreserved Osteochondral Allograft
    This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
    Other Name: ProChondrix CR

Primary Outcome Measures :
  1. Subjective International Knee Documentation Committee (IKDC) Score [ Time Frame: Baseline, 3, 6, 12, 24, 36, 48 and 60 months ]
    Change in physical pain and function as assessed by IKDC score from baseline to 60 months post-surgery

Secondary Outcome Measures :
  1. Knee injury and Osteoarthritis Outcome Score (KOOS) [ Time Frame: Baseline, 3, 6, 12, 24, 36, 48 and 60 months ]
    Change of physical pain as assessed by KOOS score from baseline to 60 months post-surgery

  2. SF-12 survey [ Time Frame: Baseline, 3, 6, 12, 24, 36, 48 and 60 months ]
    Change in functional health and well-being as assessed by SF-12 survey from baseline to 60 months post-surgery

  3. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) Scores [ Time Frame: 12, 24 and 60 months ]
    Assessment of repair cartilage structure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Skeletally mature patients between the ages of ≥18 and ≤ 60 who have a symptomatic cartilage defect (Grade 3 or 4) on the femoral condyle or patella, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between ≥ 1 cm2 and ≤ 5 cm2, measured as a rectangle length x width, as confirmed by MRI or arthroscopy.

Inclusion Criteria:

  • Patient is ≥18 and ≤ 60 years old at the time of surgery;
  • Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e. medication, bracing, physical therapy) and/or previous surgical intervention;
  • Radiographically diagnosed, by MRI, or through arthroscopy, to have a cartilage defect on the femoral condyle or patella between ≥ 1 cm2 and ≤ 5 cm2, measured as a rectangle length x width;
  • Will be having a marrow stimulation plus ProChondrix CR procedure;
  • Has an intact meniscus (maximum of ≤50% resected);
  • Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.

Exclusion Criteria:

  • Has > 5° of varus or valgus deformity;
  • Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e. > than ICRS Grade 2 on the opposing articular surface);
  • Associated damage to the underlying subchondral bone >2 mm requiring osseous repair;
  • Requires concomitant ligament repair other than Anterior Cruciate Ligament (ACL) or Medial Patella-Femoral Ligament (MPFL) reconstruction;
  • Body Mass Index (BMI)of ≥ 35 kg/m2;
  • Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
  • Clinical and/or radiographic disease in the affected joint that includes: osteoarthritis or avascular necrosis, gout or a history of gout or pseudogout, osteochondritis dissecans with significant bone loss;
  • Cartilage lesion location such that the implanted graft will not be adequately shouldered;
  • Active local microbial infection or a systemic infection, including prior or pending treatment for HIV, syphilis, Hepatitis B or Hepatitis C;
  • Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation, chemotherapy or immunosuppression;
  • Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes;
  • Has a history of any inflammatory or connective tissue disease, such as, systemic lupus erythematosus (SLE), Addison's disease, Crohn's disease, multiple sclerosis, polychondritis or rheumatoid arthritis;
  • Received hyaluronic acid injections into the joint space ≤ 90 days prior to surgery;
  • Is a female patient who is pregnant;
  • Physically or mentally compromised (i.e. being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his/her ability to participate in the clinical study;
  • Has a history of substance abuse (recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program;
  • Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;
  • Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days;
  • Has any contraindications for MRI;
  • Is a ward of the state, prisoner, or transient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03873545

Layout table for location contacts
Contact: Claire McFadyen 720-484-2452
Contact: Jill Bagdasarian 720-382-2742

Layout table for location information
United States, Kentucky
University of Kentucky Research Foundation Recruiting
Lexington, Kentucky, United States, 40506
Contact: Austin Stone, MD    859-218-3065      
Contact: Caitlin Conley, PhD    (859) 257-1939      
Principal Investigator: Austin Stone, MD         
United States, Ohio
Beacon Orthopaedics & Sports Medicine Recruiting
Cincinnati, Ohio, United States, 45247
Contact: David Argo, MD    888-773-4353   
Contact: Daniele Schum    513-354-7796   
Principal Investigator: David Argo, MD         
Sponsors and Collaborators
Layout table for investigator information
Study Director: Jill Bagdasarian AlloSource
Layout table for additonal information
Responsible Party: AlloSource Identifier: NCT03873545    
Other Study ID Numbers: PRO-002
First Posted: March 13, 2019    Key Record Dates
Last Update Posted: April 21, 2021
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AlloSource:
Cartilage Injury
Cartilage Repair
Cartilage Damage
Cartilage Lesion
Cartilage Defect